Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Sumitomo Dainippon Pharma Co ( (JP:4506) ) is now available.
Sumitomo Pharma has revised its financial forecasts for the fiscal year ending March 31, 2025, projecting improved revenue and profit figures due to strong sales of products like ORGOVYX in North America and better-than-expected performance in China. The company attributes these positive revisions to increased sales and favorable foreign exchange rates, expecting a reversal from a previously forecasted loss to a net profit of 16 billion JPY, highlighting successful business structure improvements and cost management.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a pharmaceutical company headquartered in Osaka, Japan. It focuses on developing therapeutic agents, including treatments for advanced prostate cancer, and operates in various markets, including North America and Asia.
YTD Price Performance: 5.62%
Average Trading Volume: 3,845
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.48B
For an in-depth examination of 4506 stock, go to TipRanks’ Stock Analysis page.
